Resource Summary Report

Generated by RRID on Aug 30, 2026

SH-EP

RRID:CVCL_0524
Type: Cell Line

Proper Citation

RRID:CVCL_0524

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0524

Proper Citation: RRID:CVCL_0524

Description: Cell line SH-EP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: PMID:1354203, PMID:2535691, PMID:6137586, PMID:24466371, PMID:27517323

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SH-EP

Synonyms: SHEP

Cross References: BTO:BTO_0005397, EFO:EFO_0006294, MCCL:MCC:0000423, cancercelllines:CVCL_0524, Cosmic:1212535, Cosmic:2393640, GEO:GSM1622295, IARC_TP53:23600, Progenetix:CVCL_0524, Wikidata:Q54953212

ID: CVCL_0524

Hierarchy: cvcl_0531

Record Creation Time: 20220427T221540+0000

Record Last Update: 20260829T235914+0000

Ratings and Alerts

No rating or validation information has been found for SH-EP.

No alerts have been found for SH-EP.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Hu A, et al. (2026) Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma. Theranostics, 16(6), 2866.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers, 18(3).

Gautier M, et al. (2026) A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity. Cell reports, 45(5), 117351.

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. Molecular cancer therapeutics, 25(5), 727.

Chaves GS, et al. (2026) Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clinical and translational science, 19(3), e70508.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications, 5(1), 167.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/?-Catenin Signaling, and Chemotherapy in Wilms Tumor. Pediatric blood & cancer, 72(9), e31852.

Thombare K, et al. (2024) METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. The EMBO journal, 43(24), 6310.

Delhaye L, et al. (2024) Leveraging a self-cleaving peptide for tailored control in proximity labeling proteomics. Cell reports methods, 4(7), 100818.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. Molecular oncology.

Kaufman ME, et al. (2024) Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer research communications, 4(8), 2255.

Secker C, et al. (2023) The polyphenol EGCG directly targets intracellular amyloid-? aggregates and promotes their lysosomal degradation. Journal of neurochemistry.

Jacquier A, et al. (2022) Severe congenital myasthenic syndromes caused by agrin mutations affecting secretion by motoneurons. Acta neuropathologica, 144(4), 707.

Tao L, et al. (2022) MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nature communications, 13(1), 3728.

Papadopoulos D, et al. (2022) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Molecular cell, 82(1), 159.

Jacquier A, et al. (2022) Expanding the phenotypic variability of MORC2 gene mutations: From Charcot-Marie-Tooth disease to late-onset pure motor neuropathy. Human mutation, 43(12), 1898.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer, 148(5), 1219.

Arlt B, et al. (2021) Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. Journal of enzyme inhibition and medicinal chemistry, 36(1), 1282.

Chen J, et al. (2021) Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1438.